

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 15, 2021

NANOMIX CORPORATION

(Exact name of registrant as specified in its charter)

BOSTON THERAPEUTICS, INC.

(Former name or former address, if changed since last report.)

Delaware

(State or Other Jurisdiction  
of Incorporation)

000-54586

(Commission File Number)

27-0801073

(IRS Employer  
Identification Number)

5900 Hollis Street, Emeryville, CA 95608  
(Address of principal executive offices) (zip code)

(603) 935-9799  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Not applicable		

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

On September 8, 2021, Nanomix Corporation (f/k/a Boston Therapeutics, Inc.), a Delaware corporation (the "Company"), filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") with the Secretary of State of the State of Delaware to change the Company's name to "Nanomix Corporation" effective September 17, 2021.

On September 8, 2021, the Company filed notification of the Name Change (the "Notification") with the Financial Industry Regulatory Authority ("FINRA"). In the Notification, the Company requested FINRA to authorize a new trading symbol for the Common Stock. On November 12, 2021, FINRA notified the Company that the name change to "Nanomix Corporation" and the symbol change to "NNMX" would be effective November 15, 2021.

-1-

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NANOMIX CORPORATION

Date: November 16, 2021

By: /s/ David Ludvigson  
Name: David Ludvigson  
Title: Chief Executive Officer

---